ipc&m and Flex Databases Mark the First Anniversary of a Partnership
Flex Databases, a company specialising in Professional Services Automation (PSA) for pharmaceutical industry, has announced that a successful milestone of one year of joined work has been reached with ipc&m.
ipc&m, International Pharma Consulting & Management GmbH is a trustworthy, privately held and funded company offering a comprehensive range of drug development, regulatory and management services from expert consulting to the management (inclusive monitoring) of clinical trials in the Central and Eastern European (CEE) region.
"To us, Flex Databases represent a combination rarely seen in the clinical technology field," said Dr Tobias Schmidt, Managing Director of ipc&m. "This is a platform covering technology needs which would ordinarily require multiple vendors, as it covers areas such as HR, Resource Planning, Learning Management and CTMS. And, at the same time, this is a company that possesses both outstanding software and the people who can help a user get the best out of their technology. As I started working with Flex, I quickly came to realise that when Flex promise something, they always make good on their promise."
"We are looking back on our first year with ipc&m with satisfaction which comes from a job well done," said Olga Loginovskaya, Director of Business Development and Marketing at Flex Databases. "During the course of the year ipc&m became one of our biggest endorsers. When we first came in touch ipc&m were quick to grasp all the advantages a PSA platform brings to clinical research, and we are glad to see them as excited about our technology today as they were the day we first met."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance